secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001077183-25-000151
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance
--------------------------------------------------------------------------------

- Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).
- Net loss widened 142% to $45M including $20M impairment charges.
- Adjusted EBITDA flat at $10.7M vs $10.9M last year.
- Full-year 2025 revenue guidance cut to $720-$726M (prev $747-$759M); Adj EBITDA guidance lowered to $41-$44M.
- Acquired Pathline for $8M cash plus $1M contingent consideration in April 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000151/0001077183-25-000151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000151/neo-20250729.htm
  HTML page:      https://secwatch.observer/filing/0001077183-25-000151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer